Logo image of MRUS

MERUS NV (MRUS) Stock Fundamental Analysis

NASDAQ:MRUS - Nasdaq - NL0011606264 - Common Stock - Currency: USD

54.97  -0.42 (-0.76%)

Fundamental Rating

4

Taking everything into account, MRUS scores 4 out of 10 in our fundamental rating. MRUS was compared to 559 industry peers in the Biotechnology industry. MRUS has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, MRUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRUS has reported negative net income.
In the past year MRUS has reported a negative cash flow from operations.
MRUS had negative earnings in each of the past 5 years.
MRUS had a negative operating cash flow in each of the past 5 years.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -37.94%, MRUS is in line with its industry, outperforming 58.68% of the companies in the same industry.
MRUS has a Return On Equity of -46.52%. This is in the better half of the industry: MRUS outperforms 67.44% of its industry peers.
Industry RankSector Rank
ROA -37.94%
ROE -46.52%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

MRUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRUS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MRUS has more shares outstanding
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

MRUS has an Altman-Z score of 14.45. This indicates that MRUS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 14.45, MRUS belongs to the best of the industry, outperforming 90.52% of the companies in the same industry.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.45
ROIC/WACCN/A
WACC7.58%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.86 indicates that MRUS has no problem at all paying its short term obligations.
The Current ratio of MRUS (5.86) is better than 60.11% of its industry peers.
MRUS has a Quick Ratio of 5.86. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
MRUS's Quick ratio of 5.86 is fine compared to the rest of the industry. MRUS outperforms 60.82% of its industry peers.
Industry RankSector Rank
Current Ratio 5.86
Quick Ratio 5.86
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MRUS have decreased strongly by -51.47% in the last year.
Looking at the last year, MRUS shows a very strong growth in Revenue. The Revenue has grown by 42.76%.
The Revenue has been growing slightly by 3.03% on average over the past years.
EPS 1Y (TTM)-51.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.29%
Revenue 1Y (TTM)42.76%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%235.76%

3.2 Future

The Earnings Per Share is expected to grow by 29.81% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 90.38% on average over the next years. This is a very strong growth
EPS Next Y-33.69%
EPS Next 2Y-13.06%
EPS Next 3Y-2.76%
EPS Next 5Y29.81%
Revenue Next Year53.76%
Revenue Next 2Y40.97%
Revenue Next 3Y78.41%
Revenue Next 5Y90.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

MRUS's earnings are expected to decrease with -2.76% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-2.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERUS NV

NASDAQ:MRUS (6/13/2025, 10:54:35 AM)

54.97

-0.42 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners105.59%
Inst Owner Change6.53%
Ins Owners0.57%
Ins Owner Change0.12%
Market Cap3.80B
Analysts87.5
Price Target91.42 (66.31%)
Short Float %8.49%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.76%
Min EPS beat(2)-28.18%
Max EPS beat(2)51.7%
EPS beat(4)1
Avg EPS beat(4)-10.63%
Min EPS beat(4)-62.2%
Max EPS beat(4)51.7%
EPS beat(8)4
Avg EPS beat(8)2.03%
EPS beat(12)7
Avg EPS beat(12)1.24%
EPS beat(16)10
Avg EPS beat(16)7.19%
Revenue beat(2)1
Avg Revenue beat(2)111.64%
Min Revenue beat(2)-8.95%
Max Revenue beat(2)232.22%
Revenue beat(4)2
Avg Revenue beat(4)63.79%
Min Revenue beat(4)-15.38%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)26.93%
Revenue beat(12)6
Avg Revenue beat(12)18.23%
Revenue beat(16)10
Avg Revenue beat(16)19.72%
PT rev (1m)2.23%
PT rev (3m)2.6%
EPS NQ rev (1m)-5.53%
EPS NQ rev (3m)-12.7%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-11.72%
Revenue NQ rev (1m)16.43%
Revenue NQ rev (3m)31.2%
Revenue NY rev (1m)21.85%
Revenue NY rev (3m)8.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 69.51
P/FCF N/A
P/OCF N/A
P/B 6.38
P/tB 6.4
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)-4.23
Fwd EYN/A
FCF(TTM)-3.47
FCFYN/A
OCF(TTM)-3.44
OCFYN/A
SpS0.79
BVpS8.61
TBVpS8.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.94%
ROE -46.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.26%
Cap/Sales 3.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.86
Quick Ratio 5.86
Altman-Z 14.45
F-Score3
WACC7.58%
ROIC/WACCN/A
Cap/Depr(3y)275.9%
Cap/Depr(5y)195.01%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.29%
EPS Next Y-33.69%
EPS Next 2Y-13.06%
EPS Next 3Y-2.76%
EPS Next 5Y29.81%
Revenue 1Y (TTM)42.76%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%235.76%
Revenue Next Year53.76%
Revenue Next 2Y40.97%
Revenue Next 3Y78.41%
Revenue Next 5Y90.38%
EBIT growth 1Y-80.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.38%
EBIT Next 3Y16.89%
EBIT Next 5YN/A
FCF growth 1Y-58.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.64%
OCF growth 3YN/A
OCF growth 5YN/A